Abstract:Rationale: Fc engineering has become the focus of antibody drug development. The current mutagenesis and in silico protein design methods are confined by the limited throughput and high cost, while the high-throughput phage display and yeast display technologies are not suitable for screening glycosylated Fc variants. Here we developed a mammalian cell display-based Fc engineering platform.Methods: By using mammalian cell display and next generation sequencing, we screened millions of Fc variants for optimized affinity and specificity for FcγRIIIa or FcγRIIb. The identified Fc variants with improved binding to FcγRIIIa were substituted into trastuzumab and rituximab and the effector function of antibodies were examined in the PBMC-based assay. On the other hand, the identified Fc variants with selectively enhanced FcγRIIb binding were applied to CD40 agonist antibody and the activities of the antibodies were measured on different cell assays. The immunostimulatory activity of CD40 antibodies was also evaluated by OVA-specific CD8+ T cell response model in FcγR/CD40-humanized mice.Results: Using this approach, we screened millions of Fc variant and successfully identified several novel Fc variants with enhanced FcγRIIIa or FcγRIIb binding. These identified Fc variants displayed a dramatic increase in antibody-dependent cellular cytotoxicity in PBMC-based assay. Novel variants with selectively enhanced FcγRIIb binding were also identified. CD40 agonist antibodies substituted with these Fc variants displayed activity more potent than the parental antibody in the in vitro and in vivo modelsConclusions: This approach increased the throughput of Fc variant screening from thousands to millions magnitude, enabled screening variants containing multiple mutations and could be integrated with glycoengineering technology, represents an ideal platform for Fc engineering. The initial efforts demonstrated the capability of the platform and the novel Fc variants could be substituted into nearly any antibody for the next generation of antibody therapeutics.

Genetic Engineering Antibody Fragments -A Novel Tune for the Antibody Family

New protein engineering approaches to multivalent and bispecific antibody fragments

Engineered Fc Based Antibody Domains and Fragments As Novel Scaffolds.

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds

Protein engineering approaches for antibody fragments: directed evolution and rational design approaches

The Potential of Single-Chain Variable Fragment Antibody: Role in Future Therapeutic and Diagnostic Biologics

Engineered Antibody Variable And Constant Domains As Therapeutic Candidates

Development of genetically engineered bivalent antibodies in tumor

A general Fc engineering platform for the next generation of antibody therapeutics

Engineering therapeutic monoclonal antibodies

Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use

Bioengineering of Antibody Fragments: Challenges and Opportunities

Advancing Antibody Engineering through Synthetic Evolution and Machine Learning

The Expression System of Antibody and Antibody Fragment and Strategy of High-level Production

Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications

Strategies and Applications of Antigen-Binding Fragment (Fab) Production in Escherichia coli

Improving antibodies by evolution and engineering

Advances of Technology and Strategy of Antibody Library

The role of therapeutic antibodies in drug discovery

Monoclonal antibodies: technologies for early discovery and engineering

Recent advances in antibody glycoengineering for the gain of functions